Collaborator: Moffitt Cancer Center

• Challenges and errors in genetic testing: The sixth case series

  August 1, 2026

• Cancer-specific risks associated with germline PALB2 pathogenic variants from a large clinical genetic testing cohort

  April 2, 2026

• Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variants

• Germline SDHA-related tumor risks: A cohort of 558 SDHA-positive patients from a single reference laboratory

  Presenting Author: Lauren Lovrien from Medical College of Wisconsin

  April 2, 2026

• Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variants

• Saturation genome editing-based functional evaluation and clinical classification of BRCA2 single nucleotide variants

  April 2, 2026

• Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain

• Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing

  April 2, 2026

• Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting

• BRCA1 frameshift variants leading to extended incorrect protein termini

  Rapid Fire Poster Presentation (S1-RF1).“Mutations, variants, and databases’ cagegory (group 1 on Tuesday-Wednesday)

  April 2, 2026